Modalis Receives Orphan Drug Designation for MDL-101 in CMD
25 Oct 2024 //
BUSINESSWIRE
Modalis FDA Grants Pediatric Disease Designation To MDL-101 for DMD
30 Sep 2024 //
BUSINESSWIRE
Modalis Data On Epigenome Editing For Muscular Dystrophy
07 May 2024 //
BUSINESSWIRE
Modalis Partners With Ginkgo Bioworks
12 Apr 2024 //
BUSINESSWIRE
Modalis and JCR Pharmaceuticals enter into joint research agreement
12 Dec 2023 //
BUSINESSWIRE
Modalis to Present Data of Transformative Epigenetic Editing Medicines
19 Apr 2023 //
BUSINESSWIRE